Onena Medicines

Executive Summary

Onena Medicines is a Swiss biotech company founded in 2021, leveraging AI to develop antibody therapies targeting Dual SMAD Inhibiting Proteins (DSIPs) for cancer, anemia, and obesity. Operating from Basel, Switzerland, and San Sebastian, Spain, the company aims to neutralize DSIPs, a novel class of proteins implicated in multiple diseases. While still in early preclinical stages, Onena's AI-driven platform positions it to potentially accelerate drug discovery and development. The company’s focus on three large therapeutic areas highlights its ambition, though it faces significant technical and regulatory hurdles typical for early-stage biotechs. With no disclosed funding rounds or partnerships, Onena remains a private entity requiring further validation. Its success will depend on advancing lead candidates into preclinical studies, attracting investment, and establishing strategic collaborations. The company’s innovative approach to targeting DSIPs could differentiate it in the competitive antibody landscape, but near-term catalysts are limited to early-stage milestones.

Upcoming Catalysts (preview)

• Q1 2027Publication of preclinical proof-of-concept data for lead DSIP-targeting antibody40% success
• Q2 2027Series A financing round to advance pipeline35% success
• TBDAnnouncement of research collaboration or licensing deal30% success